Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
Jennie B. Jarrett, Jeffrey Bratberg, Anne Burns, Gerald Cochran, Bethany A. DiPaula, Anna Legreid Dopp, Abigail T. Elmes, Traci C. Green, Lucas G. Hill, Felicity Homsted, Stephanie L. Hsia, Michele L. Matthews, Udi E. Ghitza, Li‐Tzy Wu, Gavin Bart
Abstract
In the last decade, the U.S. opioid overdose crisis has magnified, particularly since the introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U.S. receive MOUD. The ubiquity of pharmacists, along with their extensive education and training, represents great potential for expansion of MOUD services, particularly in community pharmacies. The National Institute on Drug Abuse's National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) convened a working group to develop a research agenda to expand OUD treatment in the community pharmacy sector to support improved access to MOUD and patient outcomes. Identified settings for research include independent and chain pharmacies and co-located pharmacies within primary care settings. Specific topics for research included adaptation of pharmacy infrastructure for clinical service provision, strategies for interprofessional collaboration including health service models, drug policy and regulation, pharmacist education about OUD and OUD treatment, including didactic, experiential, and interprofessional curricula, and educational interventions to reduce stigma towards this patient population. Together, expanding these research areas can bring effective MOUD to where it is most needed.